L-glutamic acid L-alanine

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: L-glutamic acid L-alanine
• 英文别名: (2S)-2-aminopentanedioic acid;(2S)-2-aminopropanoic acid
• 化学式: C8H16N2O6
• 分子量: 236.22
• InChiKey: WBWUIYCIVXDWHM-BHFSHLQUSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -1.32
• 重原子数：
  16
• 可旋转键数：
  5
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.62
• 拓扑面积：
  164
• 氢给体数：
  5
• 氢受体数：
  8

反应信息

• 作为产物：
  描述：

  、 钠 、 L-glutamate L-alanine 、 盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 、 、 盐酸 在 盐酸 、 sodium hydroxide 、 水 作用下， 以 水 为溶剂， 反应 88.17h， 以to give 484 mg of L-glutamic acid/L-alanine copolymer sodium salt-melphalan conjugate as a curdy solid的产率得到L-glutamic acid L-alanine
  参考文献：
  名称：

  Reactive alpha amino acid polymer

  摘要：

  具有聚合度在5至3,000之间的反应性聚合物，其整个组分单元中60摩尔％或更多的组分单元由式（I）表示的组分单元组成：## STR1 ## 其中Z表示氢原子或一价阳离子；m是整数1到4：并且在主链的羧基末端具有由式（II）表示的活性基团：## STR2 ## 其中X表示氢原子或可与相邻硫原子形成活性二硫键的基团；W是二价有机基团；并且R1表示氢原子或具有1至4个碳原子的烷基。由于这种反应性聚合物可以通过侧链的羧基与分子中含有氨基或亚氨基的细胞毒性物质结合，也可以通过主链末端的活性基团（巯基或活性二硫键基团）与例如抗肿瘤免疫球蛋白结合，因此它可以用作靶向寻找抗肿瘤药物的聚合物载体。

  公开号：

  US04385169A1

文献信息

• CONJUGATES OF WATER SOLUBLE POLYMER-AMINO ACID OLIGOPEPTIDE-DRUG, PREPARATION METHOD AND USE THEREOF
  申请人：JENKEM TECHNOLOGY CO. LTD. TIANJIN BRANCH

  公开号：US20150359900A1

  公开（公告）日：2015-12-17

  A conjugate of water soluble polymer-amino acid oligopeptide-drug of Formula (I) below and a pharmaceutical composition comprising the conjugate are provided. In the conjugate, P is a water soluble polymer; X is a linking group, wherein the linking group links P and A 1 ; each of A 1 , A 2 and A 3 is independently same or different amino acid residue or amino acid analogue residue; each of D 1 and D 2 is independently same or different drug molecule residue; a is 0 or 1; b is an integer of 2-12; c is an integer of 0-7; d is 0 or 1. The conjugate could improve drug load capacity, water solubility, stability and activity of the drug.

  提供一种水溶性聚合物-氨基酸寡肽-药物的共轭物，其化学式（I）如下，并提供包含该共轭物的制药组合物。在该共轭物中，P是水溶性聚合物；X是一个连接基团，连接基团连接P和A1；A1、A2和A3中的每一个独立地是相同或不同的氨基酸残基或氨基酸类似物残基；D1和D2中的每一个独立地是相同或不同的药物分子残基；a为0或1；b是2-12的整数；c是0-7的整数；d为0或1。该共轭物能够提高药物的载荷能力、水溶性、稳定性和活性。
• [EN] CERATAMINES A AND B, AND ANALOGUES, SYNTHESES AND PHARMACEUTICAL COMPOSITIONS THEREOF<br/>[FR] CERATAMINES A ET B, ET ANALOGUES, SYNTHESES ET COMPOSITIONS PHARMACEUTIQUES EN DECOULANT
  申请人：UNIV BRITISH COLUMBIA

  公开号：WO2005026169A1

  公开（公告）日：2005-03-24

  Antimitotic compounds and salts are provided in which the compound has the structure (formula (I)): wherein wherein X and Y are substituted or unsubstituted and are selected from carbon atoms and atoms of groups 15 and 16 of the periodic table; Z is selected from N-R, O and S; U is selected from CR1, N, NH, NR, S and O, R1, R2, and R3 are independently selected from H, NH2, NHR, NR2, SH, SR, SiR3, OH, OR, F, CI, Br, I,=O, =S and R; W is selected from O, S, and H2; R4 is selected from H, R, OH, OR, SH, SR, NH2, NHR, NR2 and halide; R is selected from H, substituted or unsubstituted aryl, and substituted or unsubstituted 1 to 20 carbon linear, branched, or cyclic, saturated or unsaturated alkyl, in which alkyl carbon atoms are replaced by 0 to 10 oxygen, 0 to 10 sulphur, and 0 to 10 N atoms; and wherein bonds to carbon atoms or to any of X, Y, Z and U are saturated or unsaturated; and providing that when W is H2, R4 is not H, OH, or unsubstituted phenyl.

  提供了具有结构（公式（I））的抗有丝分裂化合物和盐：其中X和Y是取代或未取代的，选择自周期表的15和16组元素的碳原子和原子；Z从N-R、O和S中选择；U从CR1、N、NH、NR、S和O中选择，R1、R2和R3独立选择自H、NH2、NHR、NR2、SH、SR、SiR3、OH、OR、F、CI、Br、I、=O、=S和R；W从O、S和H2中选择；R4从H、R、OH、OR、SH、SR、NH2、NHR、NR2和卤素中选择；R从H、取代或未取代的芳基和取代或未取代的1至20个碳原子的线性、支链或环状、饱和或不饱和烷基中选择，其中烷基碳原子被0至10个氧、0至10个硫和0至10个N原子取代；并且当W为H2时，R4不是H、OH或未取代的苯基。
• Methods of testing for bronchial asthma or chronic obstructive pulmonary disease
  申请人：Ohtani Noriko

  公开号：US20050208496A1

  公开（公告）日：2005-09-22

  An objective of the present invention is to provide a method of testing for bronchial asthma or chronic obstructive pulmonary disease, a method of screening for candidate compounds for treating bronchial asthma or chronic obstructive pulmonary disease, and a pharmaceutical agent for treating bronchial asthma or chronic obstructive pulmonary disease. The present invention identified genes whose expression levels varied between respiratory epithelial cells that had been stimulated by IL-13 to induce the goblet cell differentiation, and unstimulated respiratory epithelial cells. The respiratory epithelial cells were cultured according to the air interface method. The genes were revealed to be useful as markers for testing for bronchial asthma or chronic obstructive pulmonary disease and screening for therapeutic agents for such diseases. Specifically, the present invention provides methods of testing for bronchial asthma or chronic obstructive pulmonary disease and methods of screening for compounds to treat the diseases based on the comparison of the expression levels of marker genes identified as described above.

  本发明的目标是提供一种用于检测支气管哮喘或慢性阻塞性肺疾病的方法，一种筛选治疗支气管哮喘或慢性阻塞性肺疾病候选化合物的方法，以及一种治疗支气管哮喘或慢性阻塞性肺疾病的药物。本发明确定了基因，这些基因的表达水平在通过IL-13刺激诱导粘液细胞分化的呼吸上皮细胞和未受刺激的呼吸上皮细胞之间有所变化。呼吸上皮细胞是根据空气界面方法培养的。这些基因被发现可用作检测支气管哮喘或慢性阻塞性肺疾病的标记物和筛选治疗这些疾病的治疗剂的标记物。具体而言，本发明提供了一种基于上述描述的标记基因的表达水平比较的方法，用于检测支气管哮喘或慢性阻塞性肺疾病和筛选治疗该疾病的化合物的方法。
• Substituted 1-benzazepines and derivatives thereof
  申请人：Tomazic Alenka

  公开号：US20050234041A1

  公开（公告）日：2005-10-20

  This invention relates to substituted 1-benzazepines and derivatives thereof useful as anti-infective agents, to compositions, including pharmaceutical compositions, comprising such compounds, to processes for making these compounds and to methods of using these compounds for killing bacteria and other microorganisms or inhibiting bacterial and other microorganism growth.

  本发明涉及取代的1-苯并氮杂环和其衍生物，其作为抗感染剂有用，包括制备这些化合物的组合物，包括药物组合物，制备这些化合物的过程以及使用这些化合物杀死细菌和其他微生物或抑制细菌和其他微生物生长的方法。
• Acid urease and production thereof
  申请人：Takeda Chemical Industries, Ltd.

  公开号：EP0298641A2

  公开（公告）日：1989-01-11

  A novel urease having an optimal pH for activity in the acidic region is produced by a microorganism belonging to the genus Lactobacillus or Streptococcus. The urease is superior to the conventional urease in pH stability, temperature stability and alcohol stability.

  一种新型脲酶是由乳酸杆菌属或链球菌属微生物产生的，它在酸性区域具有最适宜的 pH 值。这种脲酶在 pH 值稳定性、温度稳定性和酒精稳定性方面都优于传统的脲酶。